CD7/CD56 myeloid/natural killer acute leukemia represents a novel rare distinct hematologic neoplasia. 1 According to its immunologic markers, it is classified as an acute myeloid leukemia (AML) although its clinical presentation is that typical of lymphomas. In particular, CD7/CD56 AML is characterized by an important extramedullary involvement with mediastinal masses and/or peripheral lymphoadenopathies in spite of a generally modest peripheral leucocytosis. Analysis of leukemic blasts and immunohystochemistry of adenopathies are positive for the expression of both myeloid and NK markers (CD7, CD33, CD34, CD56 and frequently HLA-DR). All rare patients relapsed or were refractory to therapies, suggesting that this disease is particularly resistant to the conventional AML chemotherapy. Premature relapse after allogenic bone marrow transplantation have also been described. 1 NF-kB is a transcription factor, which is generally composed of the p65/p50 heterodimer. In resting cells, NF-kB is retained into the cytoplasm by the inhibitory protein IkB-a. Upon stimulation, IkB-a becomes degraded and free NF-kB translocates into the nucleus, where it regulates the expression of several genes involved in survival and proliferation. NF-kB has been described as an essential transcription factor in tumorigenesis. In particular, it is believed to be necessary for myeloid leukemogenesis. 2 Recently, it has been demonstrated that NF-kB could be activated via a non-canonical pathway. [3] [4] [5] At least five kinases are responsible for the phosphorylation of p65 at Ser536. 4 This phosphorylated form of p65 is no longer subject to IkB-a inhibition and does not bind to p50. Moreover, phospho-S536-p65 can translocate to the nucleus independently to conventional stimuli, where it may regulate the expression of genes which appear to be different with respect to those regulated by IkB-a-mediated NF-kB activation. 4 In the lymphoblastic lymphoma cell line Jurkat and in primary T-cell lymphocytes, p65 is constitutively phosphorylated at Ser536. 5 In this work we have isolated leukemic blasts obtained from two CD7/CD56-positive AML and seven conventional AML blasts. Both of the CD7/CD56 AML patients' samples were collected at the time of the diagnosis. Both patients present the clinical characteristic, described by Suzuki, 1 were treated with conventional AML protocols (one received allogenic bone marrow transplantation), but both of them die for resistance to therapies.
To quantify the level of activation of the transcription factor NF-kB in CD7/CD56 AML and in conventional AML, bone marrow blasts of two CD7/CD56 AML and seven conventional AML sample have been lysed, and 20 mg of nuclear lysate has been assayed for NF-kB DNA-binding activity as described elsewhere. 6 Data have been compared with DNA-binding activity of NF-kB measured in a pool of three normal CD34 nuclear extracts. This value has been referred as 1 (Figure 1a) . In conventional AML samples, NF-kB is highly activated with a mean level of activation of six-fold. CD7/CD56 AML samples share a lower level of NF-kB activation (mean 2). To assess whether the lower NF-kB activation was associated with a Interestingly, as shown in Figure 1b , p65 is particularly overexpressed in the cytoplasm of CD7/CD56 AML blasts with respect to conventional AML samples. In this figure, one case of CD7/CD56 AML and one case of conventional AML have been analyzed as representative examples. In conventional AML and in CD7/CD56 AML, p65 has been found to be translocated into the nucleus. Interestingly, CD7/CD56 AML is characterized by the constitutive phosphorylation of p65 at Ser536, as detected in the cytoplasm and with a less extent in the nucleus. Conventional AML samples does not express Ser536-phosphorylated p65. In a recently published work, it has been demonstrated that in Jurkat cells; and in primary T-cell lymphocyte, p65 is constitutively phosphorylated at Ser536. 5 Upon stimulation, phospho-p65 translocates into the nucleus where it mediates the transcription of a putative specific set of genes, probably different with respect to those activated by conventionally activated p65. [4] [5] In Figure 1b , Jurkat cells extract has been considered as an example of known phosphorylated p65 expressing cells.
These data suggest that CD7/CD56 AML should be characterized by an IKB-a-independent activation of NF-kB as been described in T-cell lymphomas.
To assess the IkB-a independence of NF-kB activation in CD7/CD56 AML, cells have been incubated with the proteosome inhibitor MG-132, which impedes IkB-a degradation into the proteosome. MG-132-induced IkB-a stability is responsible for a permanent sequestration of NF-kB into the cytoplasm, blocking its nuclear translocation and its transcriptional activity. Guzman et al. 2 have clearly demonstrated that conventional AML blasts are sensitive to MG-132 treatment with an increase in apoptosis induction. This is because of the fact that the NF-kB constitutive activation in conventional AML is caused by the increased IkB-a kinase activity, which is responsible of an IkB-a-dependent activation of NF-kB. 7 When CD7/CD56 AML has been incubated with MG132, blasts do not undergo apoptosis (Figure 1c) . Recently, it has been demonstrated that p65 phosphorylation at Ser536 may be mediated by the expression of the Epstein-Barr virus-related protein LMP-1.
8 LMP-1 mediates a constitutive phosphorylation of p65 through the kinase IL-1 receptor-associated kinase. Immunohistochemistry has been performed on bone marrow samples, lymphoid masses of the two patients, but was negative for the expression of LMP-1 (data not shown). Taken together, these data suggest the following conclusions. First of all, from a molecular point of view, CD7/CD56 AML can be distinguished from conventional AML owing to the specific state of activation of NF-kB. Further analyses are mandatory to assess the existence of a specific serine kinase, which is responsible for the p65 Ser536 phosphorylation in CD7/CD56 AML. Buss et al. 4 have demonstrated that at least five Ser kinases converge on Ser536. They have also shown that the expression of phospho536 p65 is associated with an increase in the basal transcriptional activity owing to an efficient interaction of p65 with TAFII3. The putative Ser kinase should represent not only a key factor in the pathogenesis of CD7/CD56 AML (and T lymphomas), but also a candidate therapeutical target. Further analyses are also required to define the set of gene, whose expression is mediated by phosphoSer536-p65 in CD7/CD56 AML. Finally, these data suggest that CD7/CD56 AML is not only a distinct hematologic neoplasia with respect to conventional AML, but it should express the same molecular relationships with T-lymphoblastic lymphomas. From a clinical point of view, to try to improve the worse prognosis of this disease, we suggest to consider CD7/CD56 AML as aggressive T-lymphomas.
